New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The robotic surgery program has continually pushed the boundaries of medical technology
Majority of organizations are looking to increase investments in public and hybrid cloud
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
This project is supported by the Irish Government through IDA Ireland
Subscribe To Our Newsletter & Stay Updated
